EBR Online 2015: Obesity/Lipids
EBR Online 2015: Obesity/Lipids
Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.
This continuing medical education activity should be of substantial interest to endocrinologists, internists, and endocrine fellows preparing for the board examination or recertification; or endocrinologists and other health care practitioners seeking a review in endocrinology.
Upon completion of this educational activity, learners will be able to:
- Summarize the NIH guidelines on the assessment and treatment of overweight and obese individuals
- Identify the adverse effects of bariatric surgery, including vitamin deficiencies and non-optimal weight loss
- Manage OTC drugs with prescribed pharmacologic agents and their effect on weight loss efforts
- Describe the weight consequences of certain pharmacologic therapies for obesity
- Identify gene mutations that may cause weight issues
- Select appropriate medical therapy options for the co-management of diabetes and obesity
- Diagnose hypercholesterolemia given current medical information and lifestyle information
- Identify drugs that may have an influence on hypertriglyceridemia
- Effectively manage a patient’s diet to achieve appropriate triglyceride levels
- Identify situations where the use of lipid lowering drugs is the most effective
- Differentiate between the available drug options to provide the optimal outcome for the patient
- Identify unusual cases of hyper/hypolipidemia
- Manage cardiovascular risk in patients with lifestyle changes or pharmacologic options
- Identify secondary disorders or lipid metabolism
- Successfully complete the Lipids/Obesity/Nutrition medical content area of the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism
Endocrine Board Review Chair
David S. Cooper, MD – Johns Hopkins University School of Medicine
Richard J. Auchus, MD – University of Michigan
Shehzad S. Basaria, MD, MBBS – Brigham and Women’s Hospital
Rhonda M. Bentley-Lewis, MD, MBA – Massachusetts General Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Jennifer B. Marks, MD – University of Miami
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Elizabeth A. Streeten, MD – University of Maryland School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine
Abbie L. Young, MS, CGC, ELS(D)
The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Richard J. Auchus, MD: Consultant, Corcept Therapeutics, ISIS Pharmaceuticals, Janssen Pharmaceuticals; Investigator, Atterocor Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals; Scientific Advisory Board, Orphagen Pharmaceuticals
Rhonda M. Bentley-Lewis, MD, MBA: Committee Member and Spouse of Committee Member, Sanofi-Aventis; Consultant, Merck; Spouse of Consultant, Novartis
Daniel H. Bessesen, MD: Data Safety Monitoring Board Member, Enteromedics
Mark E. Molitch, MD: Consultant, Corcept, Eli Lilly & Co., Pfizer; Consultant and Investigator, Ipsen Pharmaceuticals, Novartis Pharmaceuticals, Novo Nordisk, Inc.
The following faculty reported no relevant financial relationships: Shehzad S. Basaria, MD, MBBS; David S. Cooper, MD; Jennifer B. Marks, MD; Elizabeth N. Pearce, MD, MSc; Elizabeth A. Streeten, MD; Margaret E. Wierman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 1.75 ABIM MOC
- 1.75 AMA PRA Category 1 Credits™
- 1.75 CME Certificate of Participation